Protein research could help in hunt for Alzheimer's and Parkinson's cures

Research carried out at the University of Kent has the potential to influence the future search for treatment of neurodegenerative diseases that are linked to a family of protein molecules known as 'amyloid'. The findings by a team of scientists led by Dr Wei-Feng Xue in the School of Biosciences could lead to a better understanding of the diseases, and suggest potential diagnostics and therapeutics strategies to combat amyloid-associated disease progression and their possible infectivity.

Currently, there is a gap in the knowledge of the factors that govern the infectious potential of amyloid in general. In an article published in the journal eLife, Dr Xue's team report on their investigations into why some forms of amyloid are highly infectious - the so-called prion form associated with BSE (Mad Cow Disease) and the human form, CJD (Creutzfeldt Jakob Disease) - while others are less infectious or even inert.

They discovered that the infectious potential of an amyloid is a complex biological property better described on a sliding scale rather than either one category (transmissible prions) or another (non-transmissible amyloid), as it is now.

Currently most amyloids apart from prions are viewed as non-transmissible between individuals meaning people would be unable to 'catch' Alzheimer's or Parkinson's simply by association. This research sheds new light on why some amyloid forms can potentially spread between cells and tissues within the same individual, and some are considered prions that are transmissible from one individual to another.

Ricardo Marchante, David M Beal, Nadejda Koloteva-Levine, Tracey J Purton, Mick F Tuite, Wei-Feng Xue.
The physical dimensions of amyloid aggregates control their infective potential as prion particles.
eLife 2017;6:e27109 doi: 10.7554/eLife.27109.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]